Thyrotoxicosis

• EMA approval · 2025-03-11
  EMA Authorised: Emcitate (tiratricol) — Rare Thyroid Therapeutics International AB

  The EMA authorised Emcitate (tiratricol) for treating thyrotoxicosis and certain hereditary neurodegenerative disorders of the nervous syste…

• FDA approval · 2020-01-06
  FDA Approved: PROPRANOLOL HYDROCHLORIDE — Original Application (Lannett Company, Inc.)

  FDA approved the original application for propranolol hydrochloride from Lannett Company, Inc., enabling a generic version to be marketed.

• FDA approval · 2018-09-19
  FDA Approved: PROPYLTHIOURACIL — Supplemental Application (Endo USA, Inc.)

  FDA approves a supplemental application for Propylthiouracil from Endo USA, Inc.

• FDA approval · 2012-01-27
  FDA Approved: PROPRANOLOL HYDROCHLORIDE — Supplemental Application (Ipca Laboratories Limited)

  FDA approved a supplemental application for propranolol hydrochloride from Ipca Laboratories Limited, finalizing a regulatory update for the…

• FDA approval · 2011-08-22
  FDA Approved: PROPYLTHIOURACIL — Supplemental Application (QUAGEN PHARMACEUTICALS LLC)

  The FDA approved a supplemental ANDA for propylthiouracil from Quagen Pharmaceuticals LLC, authorizing the marketing of an additional generi…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2010-12-15
  FDA Approved: PROPYLTHIOURACIL — Supplemental Application (Actavis Pharma, Inc.)

  The FDA approved a supplemental application for Propylthiouracil from Actavis Pharma, Inc., for the generic drug Propylthiouracil.